Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

Pankaj Gupta, Ph.D, Rhona Stein, PhD, Thomas M Cardillo, PhD, Richard R Furman, Susan Chen, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 3738.

https://doi.org/10.1182/blood.V114.22.3738.3738

Published: 2009

Journal Articles

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Diane L Nordstrom, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1590.

https://doi.org/10.1182/blood.V112.11.1590.1590

Published: 2008

Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1591.

https://doi.org/10.1182/blood.V112.11.1591.1591

Published: 2008

Journal Articles

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

Zhengxing Qu, PhD, Thomas M. Cardillo, PhD, Victoria Shi, MSc, Diana L. Delaney, MSc, Hans J. Hansen, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD,MD

Blood (2006) 108 (11): 2521.

https://doi.org/10.1182/blood.V108.11.2521.2521

Published: 2006

Journal Articles

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Puja Sapra, PhD, Rhona Stein, PhD, Jennifer Pickett, PhD, Serengulam V. Govindan, PhD, Thomas M. Cardillo, PhD, Christopher Damoci, BS, Agatha Sheerin, BS, Hans J. Hansen, PhD, Ivan D. Horak, MD, Gary L. Griffiths, PhD, David M. Goldenberg, ScD, MD

Blood (2004) 104 (11): 3287.

https://doi.org/10.1182/blood.V104.11.3287.3287

Published: 2004

NARROW

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

A Novel Anti-CD20 IgG-Interferon-α2b Fusion Protein with Potent in Vitro and in Vivo Anti-Lymphoma Activity Made by the Dock-and-Lock (DNL) Method.

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Recombinant Bispecific Monoclonal Antibody (bsMAb) Against CD20 and CD22 Active In Vitro and In Vivo Against B-Cell Lymphomas.

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only